Fusion Pharmaceuticals is focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers. Using its proprietary Fast-Clear™ Linker technology platform, Fusion attaches alpha particle emitting isotopes to targeting molecules to create novel radiopharmaceuticals for the treatment of cancer. Fusion’s lead program, FPI-1434, is currently in a Phase 1 clinical trial.

Fusion Pharmaceuticals Logo



Event details

Date: June 8 - 12, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


34 in total